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InTRoduCTIon
BInfluenza is an infectious disease caused by an in-
fluenza virus. There are 3 types of seasonal influenza
viruses: A, B and C. Type A influenza viruses are fur-
ther classified into subtypes. Among many of them,
influenza A(H1N1) and A(H3N2) subtypes, as well
as type B, are currently circulating among humans.
Type C influenza cases occur much less frequently
than A and B. There is also a new influenza virus type
identified as D. Type D primarily affects cattle and
is not known to infect or cause illness in people.
Seasonal influenza is an acute viral respiratory in-
fection that has a very efficient human transmission
mode. It is characterized by a sudden onset of symp-
toms: high fever, cough, headache, muscle and joint
pain, severe malaise and sore throat, usually described
as Influenza-Like-Illness (ILI). Common complica-
tions include pneumonia, ARDS and increased risk
of death in high-risk groups. Worldwide it is estimated
to result in about 3 to 5 million cases of severe illness
and about 250000-500000 deaths annually.1
Various antiviral agents against influenza viruses
are available in different countries. Antiviral drugs,
when timely administered, relieve symptoms and short-
en the duration of illness by 1 or 2 days. They can also
reduce the risk of complications and death.2 Ideally,
antiviral drugs need to be administered within 48
hours from the onset of symptoms. However later ad-
ministration, even after 3-5 days from the onset of
symptoms, has been proven to still reduce the risk of
complications and death, especially among high risk
individuals.2 Antiviral drugs are usually prescribed
for 5 days, although hospitalized influenza patients
may require treatment for a longer period.
There are 2 classes of antiviral drugs for influenza:
The adamantanes, amantadine and rimantadine which
are matrix protein inhibitors and the neuraminidase
(NA) inhibitors. NA inhibitors are oseltamivir,
zanamivir, peramivir and laninamivir.
Adamantanes
The antiviral drugs amantadine and rimantadine, in-
activate the viral ion channel (M2 protein), thus in-
hibiting replication of the influenza A virus. The mech-
anism of function is by utilizing the fact that influenza
viruses need acidic pH for the uncoating process. M2
protein is responsible for forming a membrane pore
allowing the hydrogen ions that generate the acidic
environment to enter into the viral particle. Adaman-
tanes cause blockage of the M2 channel, thus inhibiting
the virus from becoming acidic. Inhibition of the M2
protein function will therefore inhibit viral uncoating
and reduce viral replication and disease progression.3
The first adamantane was used as an antiviral drug
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in 1967. The adamantanes are well absorbed orally
and the usual adult dose for influenza A is 100 mg o-
rally, twice a day. After four decades of effective use
of the adamantane class of antiviral drugs in the pro-
phylaxis and treatment of influenza, global resistance
against these drugs has increased dramatically among
influenza viruses of the A(H3N2) and A(H1N1) sub-
types in recent years. In the vast majority of cases, the
basis for resistance is conferred by an S31N amino
acid variation at the M2 protein of currently circulating
A(H1N1)pdm09 and A(H3N2) viruses. Resistance
to the adamantane class of antiviral drugs by human
A(H3N2) influenza viruses currently exceeds 99% in
Europe, USA,  many Asian countries and also in
Greece. 4,5
In addition, amantadine has been associated with
several central nervous system (CNS) side effects,
likely due to amantadine’s dopaminergic activity. A-
mantadine can be prescribed to relieve the symptoms
of the Parkinson disease. CNS side effects include n-
ervousness, anxiety, agitation, insomnia and difficulty
in concentrating. Rimantadine can produce gastroin-
testinal effects such as nausea and upset stomach.
Most importantly, the increased viral resistance limits
the use of the adamantanes for the treatment of in-
fluenza, although these drugs still have a place in plan-
ning for prophylaxis during future epidemics.6
neuraminidase inhibitors
The neuraminidase inhibitor (NAI) class of influenza
antivirals first circulated in 1999 and now includes
four compounds: oseltamivir (TAMIFLU®), zanamivir
(RELENZA®), peramivir (RAPIVAD®) and lani-
namivir (INAVIR®).[7] These differ in chemical struc-
ture, bioavailability and mode of administration.
The neuraminidase inhibitor class of influenza an-
tivirals selectively inhibit the neuraminidase (NA) of
both influenza A and B viruses. These two types of
viruses possess neuraminidase on their outer surface,
an enzyme essential for the release of newly formed
viral particles from infected cells, for the prevention
of viral aggregates formation and for the viral spread
within the respiratory tract. The neuraminidase in-
hibitors are structural analogs of sialic acid, which is
the substrate of neuraminidase (NA) and the receptor
for the influenza virus. The neuraminidase inhibitors
bind to the substrate binding site of NA, thus blocking
its enzymatic activity.  This results to viral aggregation
on the host cell surface and reduction in the amount
of virus that is released and spread to infect other
cells.8
The recommended dosage of zanamivir for treat-
ment of influenza in persons aged ≥12 years is two
inhalations (one 5-mg blister per inhalation for a total
dose of 10 mg) twice daily (approximately 12 hours
apart) for 5 days and the recommended dosage of os-
eltamivir for treatment in patients aged ≥18 years is
75 mg is by oral administration, twice daily for 5 days.
Peramivir is approved and recommended for use in
adult patients of over 18 years of age. The dosage is
600 mg via intravenous infusion for 15 -30 minutes.2
Emergence of viruses with reduced NAI suscep-
tibility has been observed over the last decade both
on a local and global scale. For example in late 2007
former seasonal A(H1N1) viruses acquired the neu-
raminidase H275Y amino acid substitution which con-
ferred oseltamivir resistance, impacted clinical effec-
tiveness and spread globally in less than 12 months.9
More recently, clusters of A(H1N1)pdm09 viruses
containing the H275Y substitution, have been detected
in Hokaido, Japan and Pennsylvania, USA, probably
due to the extensive use of the drugs.10 Molecular
analysis of the neuraminidase gene of 34 influenza
A(H1N1)pdm09 virus strains that circulated during
2010-2011 in Northern Greece showed that two of
them also possessed the known resistance mutation
H275Y, whereas the rest were susceptible to os-
eltamivir. Two resistant A(H1N1)pdm09 viruses were
also identified during the first introduction of the
virus in the pandemic period.11,12 According to a pre-
vious study and to the WHO report, the resistance
mutation is more frequently induced by the use of os-
eltamivir to the patient, rather than spontaneously
occurring and persisting to the viral population.11,13
Careful use of antiviral drugs will limit the threat
of emerging antiviral resistance against NAIs. In the
majority of countries, only oseltamivir and inhaled
zanamivir are approved, with oseltamivir being the
most widely used. The policy of using influenza an-
tivirals differs around the world. Countries such as
Japan and the USA use the greatest volumes of drugs
and regularly treat influenza virus infected patients
presenting at general practitioners or hospital out-
patient clinics, while other countries,  such as Greece,
primarily use the drugs to treat severely ill patients.14
Overall, based on current analysis, >99% of influenza
viruses tested during 2014-2015 were susceptible to
all four NAIs, indicating that these antivirals remain
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an appropriate choice for the treatment and prophy-
laxis of influenza virus infections. Specifically, os-
eltamivir is considered to be the most appropriate
drug for the treatment of severe cases.14 Notably,
NAIs have also limited side effects,  most commonly
nausea, vomiting and diarrhoea.
novel anti-influenza agents
Emergence of antiviral drug resistance drives the re-
search and development of other influenza antivirals
that target viral proteins or host factors. Nitazoxanide,
favipiravir and fludase are currently in late-phase clin-
ical trials but they have not yet been approved for use
in patients with uncomplicated influenza infections.
Originally developed and commercialized as an an-
tiprotozoal agent, nitazoxanide was later identified
as a first-in-class broad spectrum antiviral drug and
has been repurposed for the treatment of influenza.
The drug  blocks maturation of the viral hemagglutinin
at the post-translational stage .The drug had no effect
on the other glycoprotein, neuraminidase, the target
of oseltamivir and zanamivir, or the M2 protein, the
target of amantadine. A phase 2b/3 clinical trial was
recently published  reporting that oral administration
of nitazoxanide, 600mg twice daily for 5 days, de-
creased the duration of clinical symptoms and reduced
viral shedding compared to placebo in patients with
laboratory-confirmed influenza.15
Favipiravir is an antiviral drug that selectively in-
hibits the RNA-dependent RNA polymerase of in-
fluenza virus. It has been found to inhibit all serotypes
and strains of influenza A, B and C viruses against
which it has been tested.  It also inhibits influenza s-
trains resistant to current antiviral drugs, and shows
a synergistic effect in combination with oseltamivir.
Favipiravir directly inhibits viral replication and tran-
scription.  A Phase III clinical evaluation of favipiravir
for influenza therapy has been completed in Japan
and two Phase II studies have been completed in the
United States.16
The development of fludase has been pioneered
by NextBio, a US start up biopharmaceutical company
that specializes in developing antiviral agents. In the
human respiratory tract, cell surface sialic acids act
as host cell receptors for influenza A and B viruses.
Fludase works by removing sialic receptors from the
airway epithelium, therefore preventing viral entry
into cells of the respiratory epithelium. Fludase com-
pleted the initial preclinical development and entered
clinical development to determine its efficiency and
safety in humans. In preclinical studies, fludase dis-
played potent antiviral activity against clinical influenza
isolates of the highly pathogenic H5N1 subtype of a-
vian influenza A.17
IndICATIonS
Generally, individuals at higher risk for influenza
complications recommended for antiviral treatment
include: children aged under 2 years, adults aged 65
years and older, pregnant or postpartum women, in-
dividuals with chronic pulmonary, cardiovascular, re-
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Figure 1: The mechanism by which antiviral drugs interrupt
the replicative cycle of influenza is illustrated. Amantadine
blocks viral internalization and uncoating. Neuraminidase
inhibitors prevent the neuraminadase from releasing bud-
ding viruses and dispersing virions.
Photo:Myra Rudakevich
nal, hepatic, haematological or metabolic disorders
and immunosuppressed people.  Notably, two of the
antiviral drugs, oseltamivir and zanamivir, are ap-
proved for children. Oseltamivir (Tamiflu®) is rec-
ommended by the CDC and American Academy of
Pediatrics for the treatment of influenza for children
aged 2 weeks and older, and for the prevention of in-
fluenza in children aged 3 months and older.
Zanamivir (Relenza®) is recommended for the treat-
ment of influenza in children aged 7 years and older,
and for the prevention of influenza in children aged
5 years and older.2
Influenza antiviral drugs can also be administered
for chemoprophylaxis. Antiviral medications are ap-
proximately 70% to 90% effective in preventing in-
fluenza and are useful adjuncts to influenza vaccina-
tion.2 Widespread or routine use of antiviral medica-
tions for chemoprophylaxis is not recommended, in
order to limit the possibility of emerging antiviral re-
sistant viruses. However, chemoprophylaxis is sug-
gested for influenza prevention in individuals that be-
long to the aforementioned high-risk groups after ex-
posure to an infectious patient during the first two
weeks following vaccination and in individuals with
severe immune deficiencies or others that might not
respond to influenza vaccination.
Clinical judgement on use of antiviral drugs and/or
antibiotics on a patient with typical ILI symptoms is
very important. Rapid Influenza Diagnostic Tests
(RIDTs) can help determine the treatment decision.
They can be useful to identify influenza virus infection
as a cause of respiratory local outbreak and epidemic.
Positive RIDT results from one or more patients with
suspected ILI can support decisions to promptly im-
plement infection prevention and control measures
for influenza outbreaks. These RIDTs are immunoas-
says that can identify the presence of influenza A and
B viral nucleoprotein antigens in respiratory speci-
mens, and rapidly display the result in a qualitative
way. RIDTs could assist in the reduction of unneces-
sary antibiotic prescriptions, in cases when antiviral
drugs would be more beneficial for the patient. Most
importantly, despite their use both for the prevention
and treatment of influenza, antiviral drugs cannot
serve as a substitute for the influenza vaccine. Effective
vaccination is considered the best way to prevent sea-
sonal influenza, while antiviral drugs will always stand
at the first line of defence for the treatment of the ac-
tual disease.
List of abbreviations:
CNS- Central Nervous System
ILI- Influenza-like-illness
M2- Matrix Protein 2
NA- Neuraminidase
NAI- Neuraminidase inhibitors
RIDTs - Rapid Influenza Diagnostic Tests 
32 Aristotle University Medical Journal, Vol. 43, Issue 3, October 2016
Aντιικά φάρμακα για την γρίπη: παρόν και μέλλον
Γιώργος Καρατσάης, Μαρία Εξηντάρη, Γεωργία Γκιούλα, Αγγελική Μελίδου
Περίληψη: Η γρίπη προκαλεί ετήσιες επιδημίες και πανδημίες με αυξημένη νοσηρότητα και θνησιμότητα. Αντιικοί
παράγοντες με διαφορετική χημική σύσταση και θεραπευτική προσέγγιση μειώνουν τη διάρκεια των συμπτωμάτων, τις
επιπλοκές και το θάνατο. Η ανάδυση ιών με ανθεκτικότητα στις αδαμαντάνες και στους αναστολείς της νευραμινιδάσης
οδηγεί σε ανάγκη για ανακάλυψη νέων αντιικών φαρμάκων.
Λέξεις κλειδιά: γρίπη, αντιικά φάρμακα, αναστολείς νευραμινιδάσης, κλινικές δοκιμές
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